title: Integrating molecular biomarkers into current clinical management in melanoma.
abstract: Personalized melanoma medicine has progressed from histopathologic features to serum markers to molecular profiles. Since the identification of activating BRAF mutations and subsequent development of drugs targeting the mutant BRAF protein, oncologists now need to incorporate prognostic and predictive biomarkers into treatment decisions for their melanoma patients. Examples include subgrouping patients by genotype profiles for targeted therapy and the development of serologic, immunohistochemical, and genotype profiles for the selection of patients for immunotherapies. In this chapter, we provide an overview of the current status of BRAF mutation testing, as well as promising serologic and molecular profiles that will impact patient care. As further research helps clarify the roles of these factors, the clinical outcomes of melanoma patients promise to be greatly improved.
authors.affiliation: Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.
authors.forename: Ragini
authors.initials: R
authors.lastname: Kudchadkar
authors.forename: Geoffrey
authors.initials: G
authors.lastname: Gibney
authors.forename: Vernon K
authors.initials: VK
authors.lastname: Sondak
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism*; D006801:Humans; D007167:Immunotherapy; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D058990:Molecular Targeted Therapy; D009362:Neoplasm Metastasis; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism* / Q000473:pathology
chemical_list: D014408:Biomarkers, Tumor